Bioabsorbable DES Reports No Thrombosis at One Year


October 23, 2007

OCTOBER 23, 2007 – Abbott’s fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease reported no stent thrombosis and a low major adverse cardiac event (MACE) rate at one year, according to results from ABSORB, the world’s first clinical trial evaluating the safety and performance of the stent, presented at TCT 2007.

The results from the 30 patient trial also showed there was no additional MACE, including no retreatment of a diseased lesion (ischemia-driven target lesion revascularization) since six months for patients who received a bioabsorbable stent.

“Abbott’s bioabsorable coronary artery stent technology has maintained initial safety and effectiveness results in patients out too one year,” said Patrick W. Serruys, M.D., Ph.D., professor of interventaional cardiology at the Throaxcentre, Erasmus University Hospital, Rotterdam, and co-principal investigator in the ABSORB study.

For more information: